{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-040585","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.700124+00:00","generated_at":"2026-06-17T06:44:48.394915+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eloxx reports Q4 net loss $6.3M, cash $19.2M; Phase 2 Alport study ongoing, IND filed for ZKN-013","bullets":["Net loss $6.3M ($2.92/share) vs $12.1M loss in Q4 2021; R&D and G&A expenses decreased YoY.","Unrestricted cash $19.2M at Dec 31, 2022; amended Hercules loan repaid $7.5M; cash runway into Q3 2023.","Three patients dosed in Phase 2 ELX-02 for Alport; initial proteinuria reduction observed; topline data H1 2023.","IND filed for ZKN-013 for RDEB; preclinical read-through up to 18-fold increase in COL VII protein."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-040585","json":"https://secwatch.observer/filing/0001104659-23-040585.json","markdown":"https://secwatch.observer/filing/0001104659-23-040585.md","text":"https://secwatch.observer/filing/0001104659-23-040585.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923040585/0001104659-23-040585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923040585/tm2311039d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:44:48.394915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"866750682768366e324da16d34d092be8bcccb84","claim":"Eloxx Pharmaceuticals, Inc. reported the three months ended December 31, 2022 results: net income net loss of $6.3 million, EPS $2.92 per share.","evidence_excerpt":"For the three months ended December 31, 2022, we incurred a net loss of $6.3 million, or $2.92 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923040585/0001104659-23-040585-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Net income","value":"net loss of $6.3 million"},{"label":"EPS","value":"$2.92 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}